Cymabay Therapeu Stock Retained Earnings
| CBAYDelisted Stock | USD 32.48 0.01 0.03% |
Cymabay Therapeu fundamentals help investors to digest information that contributes to Cymabay Therapeu's financial success or failures. It also enables traders to predict the movement of Cymabay Stock. The fundamental analysis module provides a way to measure Cymabay Therapeu's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cymabay Therapeu stock.
Cymabay |
Cymabay Therapeu Company Retained Earnings Analysis
Cymabay Therapeu's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Cymabay Therapeu Retained Earnings | (978.23 M) |
Most of Cymabay Therapeu's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cymabay Therapeu is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Cymabay Therapeu has a Retained Earnings of (978.23 Million). This is 205.03% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 110.49% higher than that of the company.
Cymabay Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cymabay Therapeu's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cymabay Therapeu could also be used in its relative valuation, which is a method of valuing Cymabay Therapeu by comparing valuation metrics of similar companies.Cymabay Therapeu is currently under evaluation in retained earnings category among related companies.
Cymabay Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (745.58) % | ||||
| Current Valuation | 3.45 B | ||||
| Shares Outstanding | 114.78 M | ||||
| Shares Owned By Insiders | 0.51 % | ||||
| Shares Owned By Institutions | 99.49 % | ||||
| Number Of Shares Shorted | 5.85 M | ||||
| Price To Earning | (8.62) X | ||||
| Price To Book | 12.76 X | ||||
| Price To Sales | 119.98 X | ||||
| Revenue | 31.07 M | ||||
| Gross Profit | (41.63 M) | ||||
| EBITDA | (101 M) | ||||
| Net Income | (105.37 M) | ||||
| Cash And Equivalents | 153.42 M | ||||
| Cash Per Share | 1.81 X | ||||
| Total Debt | 114.49 M | ||||
| Debt To Equity | 1.45 % | ||||
| Current Ratio | 12.20 X | ||||
| Book Value Per Share | 2.57 X | ||||
| Cash Flow From Operations | (72.53 M) | ||||
| Short Ratio | 0.84 X | ||||
| Earnings Per Share | (0.99) X | ||||
| Target Price | 32.5 | ||||
| Number Of Employees | 101 | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 3.73 B | ||||
| Total Asset | 434.69 M | ||||
| Retained Earnings | (978.23 M) | ||||
| Working Capital | 366.96 M | ||||
| Current Asset | 42.79 M | ||||
| Current Liabilities | 6.15 M | ||||
| Z Score | 16.7 | ||||
| Net Asset | 434.69 M |
About Cymabay Therapeu Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cymabay Therapeu's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cymabay Therapeu using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cymabay Therapeu based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cymabay Therapeu
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cymabay Therapeu position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cymabay Therapeu will appreciate offsetting losses from the drop in the long position's value.Moving together with Cymabay Stock
| 0.88 | YS | YS Biopharma | PairCorr |
Moving against Cymabay Stock
| 0.93 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.87 | VCYT | Veracyte Financial Report 2nd of May 2024 | PairCorr |
| 0.86 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.78 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.71 | DRTS | Alpha Tau Medical Financial Report 28th of May 2024 | PairCorr |
The ability to find closely correlated positions to Cymabay Therapeu could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cymabay Therapeu when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cymabay Therapeu - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cymabay Therapeu to buy it.
The correlation of Cymabay Therapeu is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cymabay Therapeu moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cymabay Therapeu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cymabay Therapeu can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Cymabay Therapeu information on this page should be used as a complementary analysis to other Cymabay Therapeu's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |